Akero Therapeutics, Inc

(NASDAQ:AKRO)

Latest On Akero Therapeutics, Inc (AKRO):

Date/Time Type Description Signal Details
2023-05-18 02:59 ESTNewsAkero Therapeutics: A Promising Solution For NASH Patients And InvestorsN/A
2023-05-17 13:48 ESTNewsAkero Therapeutics prices $220M offeringN/A
2023-05-15 20:39 ESTNewsAkero Therapeutics GAAP EPS of -$0.55N/A
2023-05-09 09:17 ESTNewsAkero Therapeutics: Proof Of Concept With EFX, Sets Up Catalyst Opportunities In 2023N/A
2023-05-07 19:00 ESTNewsAkero Therapeutics: Excellent Data, Solid Clinical Potential, No Major Near Term CatalystsN/A
2023-03-30 00:33 ESTNewsAkero plans to begin Phase 3 trial of NASH treatment in H2 after successful FDA meetN/A
2023-03-17 20:34 ESTNewsAkero Therapeutics GAAP EPS of -$0.49 beats by $0.31N/A
2023-02-08 18:19 ESTNewsAkero Therapeutics: NASH Differentiator Attractive, Awaiting Additional Price CatalystsN/A
2023-01-27 18:31 ESTNewsAkero upgraded at Morgan Stanley on NASH prospectsN/A
2022-12-08 21:25 ESTNewsAkero's liver disease drug gets FDA breakthrough therapy tagN/A
2022-11-24 02:08 ESTNewsAkero Therapeutics: What Is Making The Stock TickN/A
2022-11-04 15:25 ESTNewsAkero Therapeutics GAAP EPS of -$0.92 misses by $0.20N/A
2022-10-25 22:18 ESTNewsAkero: Putting Together The Pieces They Let Us SeeN/A
2022-09-19 18:37 ESTNewsAkero Therapeutics announces closing of upsized public offeringN/A
2022-09-19 02:04 ESTNewsAkero Therapeutics: A Promising NASH InnovatorN/A
2022-09-16 05:21 ESTNewsAkero Therapeutics: Outstanding Data In NASHN/A
2022-09-15 11:26 ESTNewsAkero Therapeutics stock slides on pricing upsized ~$200.0M stock offeringN/A
2022-09-14 18:07 ESTNewsAkero Therapeutics' Positive NASH Trial Results And Cash RaiseN/A
2022-09-14 00:37 ESTNewsAkero stock soars 71% as drug improves liver fibrosis, prevents disease worsening in trialN/A
2022-09-14 00:36 ESTNewsAkero adds over 100% rallying peers after NASH successN/A
2022-09-14 00:36 ESTNewsAkero Therapeutics commences underwritten public offering of $175M of sharesN/A
2022-08-04 23:03 ESTNewsAkero Therapeutics GAAP EPS of -$0.77 beats by $0.10N/A
2022-06-16 14:38 ESTNewsPfizer makes $25M equity investment in AkeroN/A
2022-05-06 18:49 ESTNewsAkero Therapeutics GAAP EPS of -$0.74 beats by $0.07N/A
2022-02-25 22:21 ESTNewsAkero Therapeutics GAAP EPS of -$0.93 misses by $0.13N/A
2022-02-09 07:08 ESTNewsAkero finishes enrollment in phase 2b trial of efruxifermin in liver diseaseN/A
2022-01-12 18:10 ESTNewsAkero Therapeutics (AKRO) Presents At 40th Annual J.P. Morgan Virtual Healthcare ConferenceN/A
2022-01-12 18:10 ESTNewsAkero Therapeutics (AKRO) Investor Presentation - SlideshowN/A
2021-11-12 16:26 ESTNewsAkero Therapeutics EPS beats by $0.16N/A
2021-10-20 02:11 ESTNewsAkero nabs Fast Track designation for efruxifermin for NASHN/A
2021-10-12 20:08 ESTNewsWarning: AKRO is at high risk of performing badlyN/A
2021-10-07 04:15 ESTNewsAKRO is at high risk of performing badlyN/A
2021-09-27 12:22 ESTNewsWarning: AKRO has been downgraded to Very BearishN/A
2021-09-23 22:19 ESTNewsAkero: Ticking All The Right Boxes In NASHN/A
2021-09-22 20:56 ESTNewsWarning: AKRO has been downgraded to Very Bearish.N/A
2021-09-10 16:11 ESTNewsAkero initiated with a buy at BofA on underappreciated clinical profileN/A
2021-08-13 08:25 ESTNewsAkero Therapeutics EPS misses by $0.17N/A
2021-07-20 18:14 ESTNewsAkero Therapeutics' efruxifermin meets primary endpoint in mid-stage NASH trialN/A
2021-07-20 18:08 ESTNewsAkero Therapeutics adds Judy Chou to its board of directorsN/A
2021-04-21 13:38 ESTNews89bio could close the valuation gap with Akero by end of 2021: CantorN/A
2021-03-18 12:04 ESTAnalyst RatingThe Analyst Target Price has decreased from $59.5 to $58.75.Neutral
2021-03-17 20:05 ESTFinancialsCompany financials have been released.Neutral
2021-03-17 12:03 ESTEarnings EstimateAn EPS average of -$3.73 is estimated for the 2022 year.Sell
2021-03-17 12:03 ESTEarnings EstimateAn EPS average of -$0.80 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-16 18:57 ESTNewsAkero Therapeutics EPS misses by $0.29N/A
2021-03-01 11:04 ESTAnalyst RatingThe Analyst Target Price has decreased from $60.29 to $59.5.Neutral
2020-12-13 03:07 ESTFinancialsCompany financials have been released.Neutral
2020-12-11 15:05 ESTFinancialsCompany financials have been released.Neutral
2020-11-25 11:09 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 03:04 ESTFinancialsCompany financials have been released.Neutral

About Akero Therapeutics, Inc (AKRO):

Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.

AKRO Quotes by TradingView

See Advanced Chart

General

  • Name Akero Therapeutics, Inc
  • Symbol AKRO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 13
  • Fiscal Year EndDecember
  • IPO Date2019-06-20
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.akerotx.com
View More

Valuation

  • Trailing PE 8.18
  • Price/Book (Most Recent Quarter) 4.38
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$3.88
  • Next Year EPS Estimate -$4.26
  • Next Quarter EPS Estimate -$0.55
  • Return on Assets -18%
  • Return on Equity -30%
  • Earnings Per Share -$91.75
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 1.11 billion
  • Analyst Target Price $58.75
  • Book Value Per Share $8.25
View More

Share Statistics

  • Shares Outstanding 34.77 million
  • Shares Float 17.06 million
  • % Held by Insiders 840%
  • % Held by Institutions 93.8%
  • Shares Short 2.23 million
  • Shares Short Prior Month 2.13 million
  • Short Ratio 9.66
  • Short % of Float 12%
  • Short % of Shares Outstanding 6%
View More

Technicals

  • 52 Week High $41.16
  • 52 Week Low $15.02
  • 50 Day Moving Average 31.18
  • 200 Day Moving Average 29.64
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Akero Therapeutics, Inc (AKRO) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Akero Therapeutics, Inc (AKRO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-16$N/A-$0.86-$0.59-45.76%
2020-09-302020-11-12$N/A-$0.63-$0.676.11%
2020-06-302020-08-12$N/A-$0.57-$0.627.72%
2020-03-312020-05-13$N/A-$0.42-$0.6131.15%
2019-12-312020-03-16$N/A-$0.55-$0.585.97%
2019-09-302019-11-12$N/A-$0.56-$0.43-30.69%
2019-06-302019-08-12$N/A-$0.26-$0.3628.51%

Akero Therapeutics, Inc (AKRO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Akero Therapeutics, Inc (AKRO) Chart:

Akero Therapeutics, Inc (AKRO) News:

Below you will find a list of latest news for Akero Therapeutics, Inc (AKRO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Akero Therapeutics, Inc (AKRO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-02-2112.50CALL0 099.54TRUE00
2025-02-21150CALL0 0101.57TRUE00
2025-02-2117.50CALL0 0109.12TRUE00
2025-02-21200CALL0 0103.48TRUE00
2025-02-2122.50CALL0 0102.55TRUE00
2025-02-21250CALL0 0108.07TRUE00
2025-02-2127.55.2CALL0 30105.94TRUE00
2025-02-21307.5CALL0 247102.87FALSE00
2025-02-2132.54.5CALL0 13106.11FALSE00
2025-02-21354.7CALL1 091.82FALSE4.70
2025-02-2137.52.4CALL0 486.98FALSE00
2025-02-21403.43CALL0 22691.79FALSE00
2025-02-2142.50CALL0 083.37FALSE00
2025-02-2112.50PUT0 00FALSE00
2025-02-21150PUT0 00FALSE00
2025-02-2117.50PUT0 0106.24FALSE00
2025-02-21202.6PUT0 2105.1FALSE00
2025-02-2122.53.31PUT0 75102.83FALSE00
2025-02-21255.15PUT53 1989108.07FALSE5.150
2025-02-2127.50PUT0 0106.46FALSE00
2025-02-21307.16PUT0 7597.35TRUE00
2025-02-2132.50PUT0 096.22TRUE00
2025-02-21350PUT0 098.39TRUE00
2025-02-2137.50PUT0 093.58TRUE00
2025-02-21400PUT0 093.07TRUE00
2025-02-2142.50PUT0 091.35TRUE00
2025-05-16150CALL0 091.52TRUE00
2025-05-1617.50CALL0 091.68TRUE00
2025-05-16200CALL0 092.13TRUE00
2025-05-1622.50CALL0 087.89TRUE00
2025-05-16250CALL0 087.77TRUE00
2025-05-1627.50CALL0 089.01TRUE00
2025-05-16300CALL0 090.44FALSE00
2025-05-1632.50CALL0 085.48FALSE00
2025-05-16350CALL0 091.31FALSE00
2025-05-1637.50CALL0 087.84FALSE00
2025-05-16400CALL0 084.11FALSE00
2025-05-1642.50CALL0 080.08FALSE00
2025-05-16150PUT0 099.46FALSE00
2025-05-1617.50PUT0 099.08FALSE00
2025-05-16200PUT0 093.13FALSE00
2025-05-1622.50PUT0 088.14FALSE00
2025-05-16250PUT0 082.47FALSE00
2025-05-1627.50PUT0 088.92FALSE00
2025-05-16300PUT0 089.72TRUE00
2025-05-1632.50PUT0 085.28TRUE00
2025-05-16350PUT0 094.34TRUE00
2025-05-1637.50PUT0 089.03TRUE00
2025-05-16400PUT0 082.83TRUE00
2025-05-1642.50PUT0 087.63TRUE00
2026-01-162.513CALL0 0101.98TRUE00
2026-01-1650CALL0 0208.97TRUE00
2026-01-167.50CALL0 081.32TRUE00
2026-01-16106.5CALL0 072.38TRUE00
2026-01-1612.59.25CALL0 676.19TRUE00
2026-01-16159CALL0 179.11TRUE00
2026-01-1617.510.35CALL0 482.03TRUE00
2026-01-162013.66CALL0 982.44TRUE00
2026-01-1622.512.4CALL0 1084.05TRUE00
2026-01-16257.1CALL0 3178.12TRUE00
2026-01-1627.59.3CALL0 1878.79TRUE00
2026-01-16307.4CALL0 17076.92FALSE00
2026-01-1632.56.6CALL0 1579.02FALSE00
2026-01-16356.4CALL0 1676.06FALSE00
2026-01-1637.50CALL0 074.29FALSE00
2026-01-16401.15CALL0 1474.8FALSE00
2026-01-1642.50CALL0 072.98FALSE00
2026-01-16453.7CALL0 3272.72FALSE00
2026-01-1647.50CALL0 072.89FALSE00
2026-01-16508.8CALL0 2873.16FALSE00
2026-01-16556.65CALL0 473.73FALSE00
2026-01-16600CALL0 066.85FALSE00
2026-01-16650CALL0 00FALSE00
2026-01-16700CALL0 00FALSE00
2026-01-16750CALL0 00FALSE00
2026-01-16802CALL0 1168.84FALSE00
2026-01-162.50PUT0 00FALSE00
2026-01-1650PUT0 00FALSE00
2026-01-167.50PUT0 00FALSE00
2026-01-16100PUT0 00FALSE00
2026-01-1612.52.2PUT0 50FALSE00
2026-01-16150PUT0 093.8FALSE00
2026-01-1617.54.72PUT0 287.81FALSE00
2026-01-16206.1PUT0 165285.2FALSE00
2026-01-1622.50PUT0 088.05FALSE00
2026-01-16258.5PUT0 1685.57FALSE00
2026-01-1627.50PUT0 081.65FALSE00
2026-01-16300PUT0 080.36TRUE00
2026-01-1632.50PUT0 078.09TRUE00
2026-01-16350PUT0 077.73TRUE00
2026-01-1637.518.5PUT0 575.29TRUE00
2026-01-16400PUT0 074.32TRUE00
2026-01-1642.50PUT0 076.81TRUE00
2026-01-16450PUT0 073.06TRUE00
2026-01-1647.50PUT0 074.8TRUE00
2026-01-165029.95PUT0 374.18TRUE00
2026-01-16550PUT0 074.13TRUE00
2026-01-16600PUT0 072.81TRUE00
2026-01-16650PUT0 072.68TRUE00
2026-01-16700PUT0 071.36TRUE00
2026-01-16750PUT0 075.31TRUE00
2026-01-16800PUT0 065.92TRUE00

Latest AKRO Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST22$8.07
Jun 13, 2022 7:59 PM EST11$8.07
Jun 13, 2022 7:59 PM EST14$8.06
Jun 13, 2022 7:59 PM EST10$8.07
Jun 13, 2022 7:59 PM EST47$8.07

Akero Therapeutics, Inc (AKRO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-01S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1744659/000110465920079692/0001104659-20-079692-index.htm
2020-05-20UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1744659/000000000020004520/0000000000-20-004520-index.htm
2020-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000090514820000773/0000905148-20-000773-index.htm
2020-07-08SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1744659/000090514820000781/0000905148-20-000781-index.htm
2020-09-09SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1744659/000090514820001009/0000905148-20-001009-index.htm
2020-05-15DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1744659/000091205720000169/0000912057-20-000169-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000101297520000013/0001012975-20-000013-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000101297520000022/0001012975-20-000022-index.htm
2020-01-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000101297520000029/0001012975-20-000029-index.htm
2020-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000101297520000033/0001012975-20-000033-index.htm
2020-02-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000101297520000113/0001012975-20-000113-index.htm
2020-02-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000101297520000115/0001012975-20-000115-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000101297520000119/0001012975-20-000119-index.htm
2020-02-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000101297520000267/0001012975-20-000267-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000101297520000275/0001012975-20-000275-index.htm
2020-03-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000101297520000291/0001012975-20-000291-index.htm
2020-07-06S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1744659/000104746920003964/0001047469-20-003964-index.htm
2020-07-09424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1744659/000104746920004044/0001047469-20-004044-index.htm
2020-09-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1744659/000108514620002410/0001085146-20-002410-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920001732/0001104659-20-001732-index.htm
2020-01-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920002773/0001104659-20-002773-index.htm
2020-01-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920003136/0001104659-20-003136-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1744659/000110465920003240/0001104659-20-003240-index.htm
2020-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920004440/0001104659-20-004440-index.htm
2020-01-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920005671/0001104659-20-005671-index.htm
2020-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920020276/0001104659-20-020276-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920021077/0001104659-20-021077-index.htm
2020-02-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1744659/000110465920025042/0001104659-20-025042-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920033412/0001104659-20-033412-index.htm
2020-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1744659/000110465920033680/0001104659-20-033680-index.htm
2020-03-16S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920034183/0001104659-20-034183-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920034208/0001104659-20-034208-index.htm
2020-03-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1744659/000110465920040850/0001104659-20-040850-index.htm
2020-04-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920042006/0001104659-20-042006-index.htm
2020-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920051294/0001104659-20-051294-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1744659/000110465920060866/0001104659-20-060866-index.htm
2020-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1744659/000110465920066655/0001104659-20-066655-index.htm
2020-06-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1744659/000110465920068978/0001104659-20-068978-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920069071/0001104659-20-069071-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920069072/0001104659-20-069072-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920069074/0001104659-20-069074-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920069075/0001104659-20-069075-index.htm
2020-06-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920069077/0001104659-20-069077-index.htm
2020-06-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1744659/000110465920071713/0001104659-20-071713-index.htm
2020-06-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920072520/0001104659-20-072520-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920072521/0001104659-20-072521-index.htm
2020-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1744659/000110465920074004/0001104659-20-074004-index.htm
2020-06-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1744659/000110465920078983/0001104659-20-078983-index.htm
2020-07-01S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1744659/000110465920079692/0001104659-20-079692-index.htm
2020-07-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1744659/000110465920080872/0001104659-20-080872-index.htm
2020-07-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1744659/000110465920080873/0001104659-20-080873-index.htm
2020-07-078-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1744659/000110465920081704/0001104659-20-081704-index.htm
2020-07-07S-1MEFRegistration adding securities to prior Form S-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1744659/000110465920081820/0001104659-20-081820-index.htm
2020-07-104/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920082854/0001104659-20-082854-index.htm
2020-07-104/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920082855/0001104659-20-082855-index.htm
2020-07-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920083453/0001104659-20-083453-index.htm
2020-07-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000110465920083455/0001104659-20-083455-index.htm
2020-08-07RWRegistration Withdrawal Requesthttps://www.sec.gov/Archives/edgar/data/1744659/000110465920092022/0001104659-20-092022-index.htm
2020-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1744659/000110465920093910/0001104659-20-093910-index.htm
2020-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1744659/000110465920115114/0001104659-20-115114-index.htm
2020-01-15SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1744659/000119312520008095/0001193125-20-008095-index.htm
2020-02-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1744659/000119312520028593/0001193125-20-028593-index.htm
2020-07-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1744659/000119312520192675/0001193125-20-192675-index.htm
2020-02-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000120919120008127/0001209191-20-008127-index.htm
2020-10-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1744659/000120919120054791/0001209191-20-054791-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1744659/000127417320000103/0001274173-20-000103-index.htm
2020-03-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1744659/000155837020002798/0001558370-20-002798-index.htm
2020-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1744659/000155837020006498/0001558370-20-006498-index.htm
2020-08-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1744659/000155837020010443/0001558370-20-010443-index.htm
2020-07-07EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1744659/999999999520001708/9999999995-20-001708-index.htm

Akero Therapeutics, Inc (AKRO) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Akero Therapeutics, Inc (AKRO). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 840%
Institutional Ownership: 9380%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-10-09Kevin BittermanDirectorSell13,000.0028.93376,090.0011,780.00https://www.sec.gov/Archives/edgar/data/1744659/000120919120054791/0001209191-20-054791-index.htm
2020-03-13Jonathan YoungChief Operating OfficerBuy5,035.000.623,096.53177,518.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920034208/0001104659-20-034208-index.htm
2020-03-13Jonathan YoungChief Operating OfficerBuy6,082.000.623,740.43183,600.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920034208/0001104659-20-034208-index.htm
2020-01-10Jonathan YoungChief Operating OfficerBuy17,621.000.6210,836.92211,197.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920003136/0001104659-20-003136-index.htm
2020-03-30G. Walmsley GrahamDirectorBuy2,168.0019.9743,294.962,168.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920042006/0001104659-20-042006-index.htm
2020-03-12Timothy RolphChief Scientific OfficerBuy27,368.000.6116,694.48220,277.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920033412/0001104659-20-033412-index.htm
2020-01-10Jonathan YoungChief Operating OfficerBuy21,286.000.6213,090.89232,483.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920003136/0001104659-20-003136-index.htm
2020-03-12Timothy RolphChief Scientific OfficerBuy22,656.000.6113,820.16242,933.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920033412/0001104659-20-033412-index.htm
2020-07-06Global Strategic Fund II L.P. venBio10% Share HolderSell4,603.0033.83155,721.333,033,552.00https://www.sec.gov/Archives/edgar/data/1744659/000090514820000773/0000905148-20-000773-index.htm
2020-07-02Global Strategic Fund II L.P. venBio10% Share HolderSell3,800.0033.63127,805.403,038,155.00https://www.sec.gov/Archives/edgar/data/1744659/000090514820000773/0000905148-20-000773-index.htm
2020-07-01Global Strategic Fund II L.P. venBio10% Share HolderSell108,064.0034.453,723,010.123,041,955.00https://www.sec.gov/Archives/edgar/data/1744659/000090514820000773/0000905148-20-000773-index.htm
2020-01-21Versant Venture Capital VI, L.P.10% Share HolderSell17,849.0022.39399,639.113,092,698.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920005671/0001104659-20-005671-index.htm
2020-01-21Versant Venture Capital VI, L.P.10% Share HolderSell8,091.0021.78176,221.983,110,547.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920005671/0001104659-20-005671-index.htm
2020-01-17Versant Venture Capital VI, L.P.10% Share HolderSell11,103.0020.09223,059.273,118,638.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920005671/0001104659-20-005671-index.htm
2020-01-16Versant Venture Capital VI, L.P.10% Share HolderSell22,489.0019.72443,483.083,129,741.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920005671/0001104659-20-005671-index.htm
2020-03-06Global Strategic Fund II L.P. venBio10% Share HolderSell1,800.0023.7942,830.823,150,019.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000291/0001012975-20-000291-index.htm
2020-03-05Global Strategic Fund II L.P. venBio10% Share HolderSell8,500.0023.53200,010.953,151,819.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000291/0001012975-20-000291-index.htm
2020-01-15Versant Venture Capital VI, L.P.10% Share HolderSell7,511.0019.73148,192.033,152,230.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920004440/0001104659-20-004440-index.htm
2020-01-14Versant Venture Capital VI, L.P.10% Share HolderSell12,307.0020.00246,140.003,159,741.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920004440/0001104659-20-004440-index.htm
2020-03-04Global Strategic Fund II L.P. venBio10% Share HolderSell35,650.0023.81848,765.903,160,319.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000291/0001012975-20-000291-index.htm
2020-01-13Versant Venture Capital VI, L.P.10% Share HolderSell83.0020.841,729.723,172,048.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920004440/0001104659-20-004440-index.htm
2020-01-13Versant Venture Capital VI, L.P.10% Share HolderSell11,593.0020.16233,714.883,172,131.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920004440/0001104659-20-004440-index.htm
2020-01-10Versant Venture Capital VI, L.P.10% Share HolderSell19,343.0020.10388,794.303,183,724.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920004440/0001104659-20-004440-index.htm
2020-03-03Global Strategic Fund II L.P. venBio10% Share HolderSell6,401.0023.00147,198.683,195,969.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000275/0001012975-20-000275-index.htm
2020-03-02Global Strategic Fund II L.P. venBio10% Share HolderSell10,297.0023.06237,459.123,202,370.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000275/0001012975-20-000275-index.htm
2020-01-09Versant Venture Capital VI, L.P.10% Share HolderSell16,527.0020.21334,010.673,203,067.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920002773/0001104659-20-002773-index.htm
2020-02-28Global Strategic Fund II L.P. venBio10% Share HolderSell5,100.0021.30108,652.443,212,667.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000275/0001012975-20-000275-index.htm
2020-01-08Versant Venture Capital VI, L.P.10% Share HolderSell22,368.0019.80442,886.403,219,594.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920002773/0001104659-20-002773-index.htm
2020-02-10Global Strategic Fund II L.P. venBio10% Share HolderSell7,836.0027.08212,168.323,225,861.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000119/0001012975-20-000119-index.htm
2020-02-27Global Strategic Fund II L.P. venBio10% Share HolderSell1,781.0022.5440,143.743,227,767.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000267/0001012975-20-000267-index.htm
2020-02-26Global Strategic Fund II L.P. venBio10% Share HolderSell2,523.0022.4456,615.363,229,548.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000267/0001012975-20-000267-index.htm
2020-02-25Global Strategic Fund II L.P. venBio10% Share HolderSell1,600.0023.6737,876.003,232,071.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000267/0001012975-20-000267-index.htm
2020-02-12Global Strategic Fund II L.P. venBio10% Share HolderSell6.0027.14162.843,233,671.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000119/0001012975-20-000119-index.htm
2020-02-11Global Strategic Fund II L.P. venBio10% Share HolderSell2,184.0027.0559,068.033,233,677.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000119/0001012975-20-000119-index.htm
2020-02-06Global Strategic Fund II L.P. venBio10% Share HolderSell6,102.0027.03164,954.763,233,697.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000115/0001012975-20-000115-index.htm
2020-02-05Global Strategic Fund II L.P. venBio10% Share HolderSell28,608.0025.99743,547.673,239,799.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000113/0001012975-20-000113-index.htm
2020-01-07Versant Venture Capital VI, L.P.10% Share HolderSell14,162.0020.05283,948.103,241,962.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920002773/0001104659-20-002773-index.htm
2020-01-06Versant Venture Capital VI, L.P.10% Share HolderSell42,323.0019.93843,497.393,256,124.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920001732/0001104659-20-001732-index.htm
2020-02-04Global Strategic Fund II L.P. venBio10% Share HolderSell53,731.0025.651,378,178.663,268,407.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000113/0001012975-20-000113-index.htm
2020-01-06Versant Venture Capital VI, L.P.10% Share HolderSell6,101.0018.32111,770.323,298,447.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920001732/0001104659-20-001732-index.htm
2020-01-06Versant Venture Capital VI, L.P.10% Share HolderSell4,968.0017.6887,834.243,304,548.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920001732/0001104659-20-001732-index.htm
2020-01-03Versant Venture Capital VI, L.P.10% Share HolderSell100.0020.272,027.003,309,516.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920001732/0001104659-20-001732-index.htm
2020-01-03Versant Venture Capital VI, L.P.10% Share HolderSell3,100.0019.1859,458.003,309,616.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920001732/0001104659-20-001732-index.htm
2020-01-13Global Strategic Fund II L.P. venBio10% Share HolderSell494,000.0020.239,993,620.003,322,138.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000033/0001012975-20-000033-index.htm
2020-01-08Global Strategic Fund II L.P. venBio10% Share HolderSell15,677.0019.86311,354.633,816,138.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000029/0001012975-20-000029-index.htm
2020-01-07Global Strategic Fund II L.P. venBio10% Share HolderSell31,000.0020.17625,149.103,831,815.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000022/0001012975-20-000022-index.htm
2020-01-06Global Strategic Fund II L.P. venBio10% Share HolderSell42,221.0019.64829,380.883,862,815.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000022/0001012975-20-000022-index.htm
2020-01-03Global Strategic Fund II L.P. venBio10% Share HolderSell12,498.0019.30241,213.903,905,036.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000013/0001012975-20-000013-index.htm
2020-01-02Global Strategic Fund II L.P. venBio10% Share HolderSell23,000.0019.94458,507.303,917,534.00https://www.sec.gov/Archives/edgar/data/1744659/000101297520000013/0001012975-20-000013-index.htm
2020-01-02Versant Venture Capital VI, L.P.10% Share HolderSell1,000.0022.1722,170.003,996,859.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920001732/0001104659-20-001732-index.htm
2020-01-02Versant Venture Capital VI, L.P.10% Share HolderSell3,900.0021.2082,680.003,997,859.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920001732/0001104659-20-001732-index.htm
2020-01-02Versant Venture Capital VI, L.P.10% Share HolderSell10,952.0019.89217,835.284,001,759.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920001732/0001104659-20-001732-index.htm
2020-07-10Apple Tree Partners IV, L.P.10% Share HolderBuy415,000.0036.0014,940,000.005,830,203.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920083455/0001104659-20-083455-index.htm
2020-07-10Seth Loring HarrisonDirectorBuy415,000.0036.0014,940,000.005,830,203.00https://www.sec.gov/Archives/edgar/data/1744659/000110465920083453/0001104659-20-083453-index.htm